

Vermont Medicaid ACO Pilot

2014 Benchmarks

Statewide baseline data and benchmarks for each of the payment measures for the first measurement year of the Medicaid ACO Pilot, CY2014, appear below.

#	Measure and Source	Proxy for Statewide Baseline ¹ 2012 VT Medicaid Performance	Benchmark <i>HEDIS Medicaid or State- developed Medicaid benchmarks</i>
Core-1	All-Cause Readmissions <i>Source: NQF #1768,</i>	16.60	National benchmark not available. 3 pt: statistically significant improvement over baseline 2 pt: no statistically significant change over baseline 0 pt: statistically significant decline over baseline <i>Please note, when interpreting this measure, a lower score indicates better performance.</i>
Core-2	Adolescent Well-Care Visits <i>Source: HEDIS AWC (Not NQF endorsed)</i>	46.27	3 pt: Nat. 75 th : 57.07 2 pt: Nat. 50 th : 47.24 1 pt: Nat. 25 th : 41.72
Core-3	Cholesterol Management for Patients with Cardiovascular Conditions (LDL-C Screening Only for Year 1) ² <i>Source: HEDIS CMC (Not NQF endorsed)</i>	45.67	3 pt: Nat. 75 th : 85.20 2 pt: Nat. 50 th : 82.36 1 pt: Nat. 25 th : 78.44

¹ Actual statewide baseline performance cannot be calculated until ACO attribution has been finalized.

² Core-3 is counted in both the "payment" and "pending" categories since the claims-based HEDIS measures "Cholesterol Management for Patients with Cardiovascular Conditions" (LDL-screening only) will be used for payment until the clinical data-based Complete Lipid Panel and LDL Control are ready to be used for payment, at which point, it will replace LDL screening.

#	Measure and Source	Proxy for Statewide Baseline ¹ 2012 VT Medicaid Performance	Benchmark <i>HEDIS Medicaid or State- developed Medicaid benchmarks</i>
Core-4	Follow-Up After Hospitalization for Mental Illness: 7-day <i>Source: NQF #0576, HEDIS FUH</i>	42.01	3 pt: Nat. 75 th : 54.64 2 pt: Nat. 50 th : 43.95 1 pt: Nat. 25 th : 30.91
Core-5	Initiation and Engagement for Substance Abuse Treatment: Initiation and Engagement of AOD Treatment (composite) <i>Source: NQF #0004, HEDIS IET</i>	33.22	3 pt: Nat. 75 th : 29.64 2 pt: Nat. 50 th : 24.75 1 pt: Nat. 25 th : 20.59
Core-6	Avoidance of Antibiotic Treatment for Adults With Acute Bronchitis <i>Source: NQF #0058, HEDIS AAB</i>	28.62	3 pt: Nat. 75 th : 28.07 2 pt: Nat. 50 th : 22.14 1 pt: Nat. 25 th : 17.93
Core-7	Chlamydia Screening in Women <i>Source: NQF #0033, HEDIS CHL</i>	51.18	3 pt: Nat. 75 th : 63.72 2 pt: Nat. 50 th : 57.15 1 pt: Nat. 25 th : 50.97
Core-8	Developmental Screening in the First Three Years of Life (Medicaid-only measure) <i>Source: NQF measure #1399 (and CHIP Child Core measure #8)</i>	30.17	National benchmark not available. 3 pt: statistically significant improvement over baseline 2 pt: no statistically significant change over baseline 0 pt: statistically significant decline over baseline